Compare · RLX vs SGTX
RLX vs SGTX
Side-by-side comparison of RLX Technology Inc. (RLX) and Sigilon Therapeutics Inc. (SGTX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both RLX and SGTX operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- RLX is the larger of the two at $3.05B, about 52.5x SGTX ($58.2M).
- RLX has hit the wire 2 times in the past 4 weeks while SGTX has been quiet.
- SGTX has more recent analyst coverage (8 ratings vs 2 for RLX).
- Company
- RLX Technology Inc.
- Sigilon Therapeutics Inc.
- Price
- $1.98-0.75%
- $22.53-2.57%
- Market cap
- $3.05B
- $58.2M
- 1M return
- -7.91%
- -
- 1Y return
- -10.41%
- -
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- 2020
- News (4w)
- 2
- 0
- Recent ratings
- 2
- 8
RLX Technology Inc.
RLX Technology Inc., together with its subsidiaries, researchers, develops, manufactures, distributes, and sells e-vapor products in the People's Republic of China. It serves RELX branded partner stores and other retail outlets through distributors. RLX Technology Inc. was founded in 2018 and is based in Beijing, China.
Sigilon Therapeutics Inc.
Sigilon Therapeutics, Inc., a biopharmaceutical company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate-severe to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neurological manifestations of the disease in patients with mucopolysaccharidosis type 1; SIG-007 to provide continuous and prolonged release of functional enzyme at levels sufficient to produce clinical benefits and alleviate progression of the downstream aspects of Fabry disease; and SIG-002 designed to replace islet cells for the treatment of type 1 diabetes. The company was formerly known as Sigilon, Inc. and changed its name to Sigilon Therapeutics, Inc. in June 2017. Sigilon Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.
Latest RLX
- SEC Form 6-K filed by RLX Technology Inc.
- RLX Technology Announces Unaudited First Quarter 2026 Financial Results
- RLX Technology to Report First Quarter 2026 Financial Results on May 20, 2026
- RLX Technology Files 2025 Annual Report on Form 20-F
- SEC Form 20-F filed by RLX Technology Inc.
- SEC Form 3 filed by new insider Wang Ying Kate
- SEC Form 3 filed by new insider Jiang Long
- SEC Form 3 filed by new insider Xi Youmin
- SEC Form 3 filed by new insider Wen Yilong
- SEC Form 3 filed by new insider Lu Chao
Latest SGTX
- SEC Form SC 13G/A filed by Sigilon Therapeutics Inc. (Amendment)
- SEC Form 15-12G filed by Sigilon Therapeutics Inc.
- SEC Form EFFECT filed by Sigilon Therapeutics Inc.
- SEC Form 4 filed by Flagship Ventures Fund V General Partner Llc
- Over $25M Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buying
- SEC Form SC 13D/A filed by Sigilon Therapeutics Inc. (Amendment)
- SEC Form 4: Eli Lilly & Co bought $25,639,916 worth of shares (1,718,493 units at $14.92)
- Lilly Completes Acquisition of Sigilon Therapeutics
- SEC Form S-8 POS filed by Sigilon Therapeutics Inc.
- SEC Form S-8 POS filed by Sigilon Therapeutics Inc.